<DOC>
	<DOCNO>NCT00135005</DOCNO>
	<brief_summary>This study open-label , multicenter , Phase I dose-escalation study combination AMN107 imatinib ( STI571 ) patient imatinib-resistant GIST . This study design determine Phase II dose AMN107 imatinib administer together patient imatinib-resistant GIST , characterize safety , tolerability pharmacokinetic ( PK ) profile combination .</brief_summary>
	<brief_title>Study AMN107 With Imatinib Gastrointestinal Stromal Tumors ( GIST )</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients gastrointestinal stromal tumor ( GIST ) . Patients disease progression imatinib therapy 800 mg. Ability understand willingness sign write informed consent document . Patients prior concomitant malignancy GIST exception previous concomitant basal cell skin cancer previous cervical carcinoma situ . A history impaired cardiac function uncontrolled cardiovascular disease . Severe and/or uncontrolled concurrent disease could cause unacceptable safety risk impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption AMN107 . Currently take certain medication could affect electrocardiogram result . Women pregnant breast feeding . Patients unwilling unable comply protocol . NOTE : Additional inclusion and/ exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>GIST</keyword>
	<keyword>AMN107</keyword>
	<keyword>Gastrointestinal Stromal Tumors</keyword>
</DOC>